title: Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
abstract: OBJECTIVE
  The objective was to determine the effects of aripiprazole on hostility.
  
  
  METHODS
  A total of 1476 patients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were the subjects in 5 short-term, double-blind studies comparing aripiprazole with placebo; 3 of these studies also included a comparison with haloperidol. The studies were conducted between December 1993 and January 2001. The Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure in these studies. To determine the effect of aripiprazole on hostility, post hoc analyses of the hostility item from the PANSS were conducted for the first 4 weeks of treatment.
  
  
  RESULTS
  Aripiprazole was superior to placebo and not significantly different from haloperidol in reducing hostility.
  
  
  CONCLUSIONS
  Aripiprazole is an effective treatment for hostility in patients with schizophrenia or schizoaffective disorder.
authors.affiliation: The Nathan Kline Institute and New York University, 140 Old Orangeburg Road, Orangeburg, N.Y. 10962, USA. janvolavka@gmail.com
authors.forename: Jan
authors.initials: J
authors.lastname: Volavka
authors.forename: Pal
authors.initials: P
authors.lastname: Czobor
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome
authors.forename: Robert D
authors.initials: RD
authors.lastname: McQuade
authors.forename: William H
authors.initials: WH
authors.lastname: Carson
authors.forename: Dusan
authors.initials: D
authors.lastname: Kostic
authors.forename: Sterling
authors.initials: S
authors.lastname: Hardy
authors.forename: Ronald
authors.initials: R
authors.lastname: Marcus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006791:Hostility; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D015363:Quinolones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D010919:Placebos; D015363:Quinolones; D000068180:Aripiprazole; D006220:Haloperidol